Fulgent Genetics insider sale: 1,063 shares sold to cover RSU taxes

Rhea-AI Filing Summary

Gao Hanlin, Chief Scientific Officer of Fulgent Genetics, Inc. (FLGT), reported the sale of 1,063 shares of the issuer's common stock on 09/03/2025. The filing states the shares were sold to satisfy tax withholding obligations arising from the vesting of restricted stock units originally granted on 02/28/2022. The shares were sold in multiple transactions at prices ranging from $21.92 to $22.175, with a reported weighted-average sale price of $22.0267. Following the reported sale, the reporting person beneficially owns 957,085 shares, held directly.

Insights

Corporate Governance Expert

TL;DR: Routine insider sale to cover tax withholding after RSU vesting; disclosure is standard and not a governance red flag.

The Form 4 discloses a small, specific disposition of 1,063 shares by the Chief Scientific Officer to satisfy tax obligations tied to RSU vesting from February 28, 2022. The filing provides price details and the post-transaction beneficial ownership of 957,085 shares, indicating continued substantial ownership. This transaction is described as a taxation-driven sale rather than a discretionary liquidity event, and the filing includes the weighted-average price plus the range of execution prices. From a governance perspective, the clear explanation and timely reporting align with disclosure best practices.

Securities Analyst

TL;DR: Small-scale insider sale for tax withholding with transparent pricing; impact on share float and control is negligible.

The sale of 1,063 shares at an average price of $22.0267 (range $21.92 to $22.175) is documented as resulting from RSU vesting-related withholding. The reporting person retains 957,085 shares after the sale, indicating significant residual stake. The filing notes multiple transactions and offers to provide transaction-level detail on request. For market impact, the size of the disposition is minor relative to typical public-company floats and should not materially affect valuation or control metrics based on the information provided.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Gao Hanlin

(Last) (First) (Middle)

C/O FULGENT GENETICS, INC.

4399 SANTA ANITA AVENUE

(Street)

EL MONTE CA 91731

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Fulgent Genetics, Inc. [ FLGT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Scientific Officer

3. Date of Earliest Transaction (Month/Day/Year)
09/03/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/03/2025		S		1,063(1)	D	$22.0267(2)	957,085	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The shares were sold by the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on February 28, 2022, which grant was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on March 2, 2022.

2. The shares were sold in multiple transactions at prices ranging from $21.92 to $22.175, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.

	/s/ Paul Kim as Attorney-in-Fact	09/03/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What transaction did Gao Hanlin report on Form 4 for FLGT?

The report discloses the sale of 1,063 shares of Fulgent Genetics common stock on 09/03/2025.

Why were the shares sold by the reporting person in the FLGT Form 4?

The filing states the shares were sold to satisfy tax withholding obligations arising from the vesting of restricted stock units granted on 02/28/2022.

At what prices were the FLGT shares sold according to the Form 4?

Sales occurred in multiple transactions at prices ranging from $21.92 to $22.175; the weighted-average sale price was $22.0267.

How many FLGT shares does the reporting person own after the reported sale?

After the transaction the reporting person beneficially owns 957,085 shares, held directly.

Does the Form 4 indicate who signed the filing for Gao Hanlin?

Yes, the form is signed by /s/ Paul Kim as Attorney-in-Fact with date 09/03/2025.